INTRO – WHY THESE QUESTIONS MATTER

If you scroll through biotech write-ups online – reports, threads, tweets, forum posts – everything often sounds easy: two PDUFAs coming up, a Phase 3 “that cannot possibly fail”, a CEO who “knows something we don’t”, and price targets based on “if things go well, this could 5x”.

Reality is messier. Clinical development is slow, regulators are conservative, and capital markets can turn hostile exactly when a company needs money the most. The story that looked clean on a slide can become complicated in real life: delays, protocol changes, CRLs, safety signals, dilution at the worst possible time.

If you want to own biotech stocks without constantly being blindsided, you need to stop for a moment and ask yourself a few questions before you even consider the stock. Not a rigid checklist you must fill like a form, but a mental grid that you quickly run in the background every time a new ticker appears on your screen.

Most of all, these questions help you avoid the classic traps:

• treating noise (social media, chat rooms, Stocktwits) as signal (data, filings, trials),
• falling in love with a single catalyst and ignoring cash, burn, ownership and competition,
• forgetting who pays the bill (cash, dilution) or who decides (FDA, EMA, payers, management, big holders).

The goal is not to become an expert in everything overnight. The goal is simply to move from “I like the chart and the story” to “I know what I am really betting on, what can go wrong, and whether the risk fits my size, horizon and temperament”.

DO I UNDERSTAND THE DISEASE AND THE STANDARD OF CARE?

You do not need to be a doctor, but you do need a basic map of the battlefield. A drug does not live in a vacuum: it competes against existing therapies, guidelines, prescriber habits and payer preferences.

• What disease is this drug targeting – ultra-rare/orphan, niche, or a crowded mass market?
• What does the current standard of care (SOC) look like? Is it one dominant drug, multiple options, or essentially “no good treatment”?
• Are there already effective drugs, or is the unmet need huge and obvious to every clinician in the field?

Then ask yourself: If I were the treating physician, why would I switch from what I use today to this new drug? Doctors are conservative for good reasons: they know the side effects of current drugs, they know how to manage them, and they are held accountable by guidelines and payers.

If your only answer is “because the company says it is great” or “because the trial hit the endpoint”, that is not enough. You want to see how the drug translates into real practice: fewer hospitalizations, better quality of life, easier monitoring, fewer interactions, lower cost, or access to a population that today has no real option.

Even a basic understanding of the disease and SOC will often tell you whether the story is about “a slightly better version of what already exists” or about a real change in how the disease is treated. The market may treat both as “catalysts”, but the long-term value is very different.

WHAT IS THE TRIAL DESIGN REALLY TELLING ME?

Before you glance at the chart, look at the trial design for the key catalyst. The same headline (“Phase 3 met primary endpoint”) can mean very different things depending on how the study was built.

• Phase (1/2/3) and study size: is it a small signal-finding study or a large registration trial?
• Randomized vs single-arm; placebo or active control vs historical controls.
• Primary endpoint, key secondaries and follow-up duration: are they robust, or is the story built on a surrogate that regulators may not like?

Ask whether the endpoint is clinically meaningful, whether the control arm is robust, and what obvious pitfalls exist (heterogeneous population, weak statistics, risky surrogates, complex composite endpoints). A weak design does not mean the stock cannot run into the event – the market often trades the “headline” – but it does mean the odds of a brutal surprise are higher once the detailed data are published.

You do not need to model every variable. But you do want a sense of whether:

• the trial is built to give a clean yes/no answer, or
• the trial is so messy that any result will be “open to interpretation”.

The first case can still be risky but is easier to price. The second case often leads to volatile reactions, confused reactions from the sell side, and longer debates with regulators and payers – not ideal if you were hoping for a quick “derisking” moment.

HOW MUCH CASH, HOW MUCH BURN, HOW LONG IS THE RUNWAY?

Biology can be unforgiving. So can the balance sheet. A great drug in the hands of a company that runs out of cash at the wrong moment can destroy a lot of shareholder value, even if the science eventually wins.

• How much cash and marketable securities does the company have today (roughly)?
• What is the annualized burn (R&D + SG&A), adjusted for any obvious one-offs?
• How many quarters of runway does that imply if they keep spending at a similar pace?

Then ask: can they reasonably reach the next major catalyst with current resources, or will they need to raise cash before the big event? If a financing is almost guaranteed pre-catalyst, you are taking financing risk on top of trial risk.

In practice, that can mean:

• an equity raise at depressed prices, diluting existing holders just before the most important data,
• an ATM program that slowly leaks shares into the market, capping rallies,
• or debt with covenants that reduce flexibility exactly when the company needs it.

None of this is a reason to avoid every cash-burning biotech. But you want to know whether your thesis is “ride the run-up into a catalyst with a decent cash cushion” or “hope that they can finance themselves without crushing the stock”. Those are very different setups.

WHO ELSE HOLDS THE SHARES – INSIDERS, INSTITUTIONS, SHORTS?

Look at the cap table before you commit. You are not investing in a vacuum: you are entering an existing ecosystem of holders, each with their own constraints and time horizon.

• Insiders: do they own a meaningful stake, or just token amounts that do not really hurt if things go wrong?
• Institutions: are there serious long-term funds on board, or mostly fast money and trading vehicles?
• Short interest: negligible, moderate, or high (>10–15% of float)? Is it a thoughtful hedge or pure “meme squeeze” fuel?

You do not have to follow any of them blindly. But you should know whether you are sitting at a table full of impatient traders, concentrated specialist funds, or a more balanced mix of holders. Each structure reacts differently to good and bad news.

High short interest is not automatically bullish or bearish. It can mean:

• the company is genuinely overvalued with weak fundamentals, or
• the stock has become a consensus hedge or a crowded bet against retail enthusiasm.

Both scenarios can be tradable, but the path and the volatility will be different. Knowing who else is in the boat helps you prepare emotionally for how the stock might react when the tide turns.

CAN I LIVE WITH THE WORST-CASE SCENARIO?

Finally, the question that often decides whether you should touch a biotech at all:

“If the next big catalyst goes wrong and the stock drops 60–80%, can I live with that – financially and mentally – given my size and timeframe?”

This is not a theoretical question. In biotech, large gaps down do happen. The difference between a painful drawdown and a portfolio-destroying event is often just position sizing and honesty with yourself beforehand.

If the honest answer is “no”, the position is too big, or the stock is not for you. Biotech is asymmetric: that is part of the appeal – sometimes one winner can pay for several losers. But asymmetry only works if you are still able to think clearly after the losers, not if each one threatens your overall capital.

A good discipline is to decide in advance:

• whether you will hold through the catalyst or trade only the run-up,
• how much capital you are truly willing to see go to zero on that single name,
• and what kind of news (positive or negative) would make you re-evaluate the thesis instead of reacting emotionally.